This sponsored article, featuring Craig Hopkinson, M.D., Alkermes' Chief Medical Officer, originally appeared in Scrip in December 2021.
The unmet medical need in oncology is changing. While immunotherapies have transformed the treatment of some cancers, they are only available to, and effective in, a small subset of patients. Bringing the power of immunotherapies to more patients is now the defining challenge of oncology R&D. Recognizing that, Alkermes is using R&D capabilities honed over 30 years of work on complex, hard-to-treat diseases to investigate a potential next breakthrough in cancer therapy.